Syntaxin (United Kingdom) a preclinical-stage biopharmaceutical company focusing on targeted secretion inhibitors for the potential treatment of pain, endocrine disease and cancer, closed a $28.3M Series C financing. Participants include Lundbeckfond Ventures, Ipsen, Seventure Partners, Abingworth, SROne, Life Science Partners, Johnson & Johnson Development Corp and Quest for Growth.